Abstract: SARS-CoV-2 was identified as variant Alpha (PANGO lineage B.1.1.7) with mutation S:E484K.
Result: Interestingly, 23012G > A (S:E484K) was already technically fixed (VAF > 0.95) at the first time point, but its frequency decreased at T2 and T3 going down to 0.49-0.72.
Result: SARS-CoV-2 was classified as an Alpha variant (Phylogenetic Assignment of Named Global Outbreak Lineages-PANGO-lineage B.1.1.7), similar to the consensus sequences of dominant contemporaneous isolates circulating by the same
Discussion: Interestingly, E484K was already fixed at the first time point, but waned at the second and third time points.
Discussion: The S:E484K mutation alters antibody recognition.
Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.
Introduction: Different spike mutations emerged and became dominant in the emerged variants of concern (VOC), such as the representative mutations D614G, N501Y, E484Q/K, L452R, P681R in the Alpha, Beta, Gamma, and Delta variants.
Discriminatory Weight of SNPs in Spike SARS-CoV-2 Variants: A Technically Rapid, Unambiguous, and Bioinformatically Validated Laboratory Approach.
Introduction: The Beta variant, discovered a few days after the Alpha in samples collected between March and November 2020, also carries the N501Y mutation (phylogenetically not related to the Alpha variant) and other peculiar substitutions in the S gene:D80A, D215G, E484K, N501Y, and A701V.
Introduction: The Gamma variant emerged in February 2020 and is associated with the E484K, K417N, N501Y, and H655Y mutations in the S gene.
Introduction: The Iota variant has six mutations on the spike gene (L5F
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Abstract: Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant.
Introduction: The Spike of Mu accumulated the following mutations: insertion in 146N, T95I, Y144T and Y145S, in the N-terminal domain (NTD); R346K, E484K, N501Y in the receptor-binding domain (RBD) and P681H at the S1/S2 interface.
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Figure: (a, b) Binding of the antibodies to the RBD carrying the individual mutations (N501Y, N439K, E484K, K417N) and RBD with triple mutation N501Y/E484K/K417N were analysed.
Figure: ACE2 is shown in a green cartoon model, RBD as a grey surface model, mutations N439K (within AX677 binding site) and E484K (wi
Discussion: The antibodies were oblivious to the E484K mutation, which has been recently shown to endow the S-typed VSV pseudovirus with resistance to several human convalescent sera.
Multiplexed Lab-on-a-Chip Bioassays for Testing Antibodies against SARS-CoV-2 and Its Variants in Multiple Individuals.
Abstract: The concentrations of antibodies against RBD, D614G, N501Y, E484K, and L452R/E484Q-mutants after two doses of vaccines are 6.6 +- 3.6, 8.7 +- 4.6, 3.4 +- 2.8, 3.8 +- 2.8, and 2.8 +- 2.3 ng/mL, respectively.
Abstract: This suggests that neutralizing activities against N501Y, E484K, and L452R/E484Q-mutants were less effective than RBD and D614G-mutant.
Introduction: Each test can detect six targets (RBD, D614G, N501Y,
Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.
Introduction: Here, we describe three infections with rare E484K-harboring SARS-CoV-2 containing three other amino acid substitutions in the spike, including W152L, which is located in the N-terminal domain (NTD) and possibly reduces sensitivity to neutralizing antibodies, and D614G and G679V, located in the S2 subunit.
Introduction: Interestingly, the surface potential of the RBD was markedly increased by substitution E484K.
Introduction: The low level of circulation of this variant in France and worldwide, with the notable exceptions of Japan and the USA, contrasts with the dramatic spread of other E484K-harboring viruses such as lineages B.1.351 and B.1.1.28/P.1.|mgd
Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.
Result: A number of these variants have RBD mutations such as L452R, E484K, and/or N501Y, which are thought to promote human ACE2 binding.
Result: B.1.1.7/E484K, Iota/B.1.526 + E484K (first associated with infections in New York), Eta/B.1.525 (a variant with associations with West Africa), and L452R (in multiple variants of concern, including Epsilon/B.1.427/B.1.429, first associated with infections in California, and Delta/B.1.617.2, which is currently replacing all other SARS-CoV-2 lineages globally) all allowed pseudovirus to use ferret ACE2 for cell
Figure: Alpha also known as B.1.1.7; Beta also known as B.1.351; Gamma also known as P.1; Eta also known as B.1.525; Iota also known as B.1.526 + E484K.
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
PMID: 35093484
2022
The Journal of allergy and clinical immunology
Abstract: Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected.
Abstract: We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants.
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
Result: 2 , D35 GMTs against variants with the E484K/Q mutation were lower than those against D614 by 13.9- and 34.8-fold to Beta and by 8.4- and 20.5-fold to Gamma for Groups 1 and 2, respectively.
Result: At D35, neutralizing titers against Alpha, Delta, and Epsilon variants, without the key E484K/Q mutation, were comparable to those against D614 with GMTs to D614, Alpha, and Epsilon all around the order of 3.3-3.5 log10.
Result: F
Result: collectively demonstrated that the third booster vaccination, even with the vaccines containing the original D614 Spike protein sequence, can effectively improve the quality of vaccine-induced neutralizing antibody responses by expanding the breadth of coverage against VoC, especially those harboring the key E484K/Q mutation.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Microorganisms
Browser Board
Co-occurred Entities
Filtrator
ViMRT